Obinutuzumab treatment of a DLBCL patient subgroup

A method of treating a patient having a diffuse large B-cell lymphoma (DLBCL), the method comprising administering to the patient a therapeutically effective amount of a humanized Type II anti-CD20 antibody, wherein a tumor sample from the patient has a germinal center B-cell-like (GCB) cell-of-origin (COO) status;

• wherein the humanized Type II anti-CD20 antibody comprises a heavy chain variable region comprising an amino acid sequence having at least 90% identity to SEQ ID NO:
• 1 and a light chain variable region comprising an amino acid sequence having at least 90% identity to SEQ ID NO:
• 2;
• and
• wherein the GCB COO status is a strong GCB COO status identified by a linear predictor score (LPS) for the tumor sample that is less than 1141, and wherein the LPS is a weighted sum of the expression levels of the genes TNFRSF13B, LIMD1, IRF4, CREB3L2, PIM2, CYB5R2, RAB7L1, CCDC50, MME, SERPINA9, ASB13, MAML3, ITPKB, MYBL1, S1PR2, R3HDM1, WDR55, ISY1, UBXN4, and TRIM56 and is calculated according the formula:
• LPS(X)=ΣjajXj,
• wherein Xj is the gene expression for gene j and aj is the coefficient for gene j.